Immune profiling of cancer patients in the Spanish Immunotherapy Registry of Cardiovascular Toxicity (SIR-CVT)
Pilar Martı́n(Spanish National Centre for Cardiovascular Research), Teresa López‐Fernández(Hospital Universitario La Paz), Ignacio Ruiz‐Fernández(Spanish National Centre for Cardiovascular Research), Pedro Moliner(Bellvitge University Hospital), Ana Martín‐Garcia(Complejo Hospitalario de Salamanca), J. De Castro Carpeño(Hospital Universitario La Paz), Carmen Jiménez López-Guarch(Research Institute Hospital 12 de Octubre), Sònia Pernas, T Lozano Palencia(Hospital General Universitario de Alicante Doctor Balmis), Cristina Mitroi(Hospital Universitario Puerta de Hierro Majadahonda), Eduardo Nicolás(Hospital General Universitario Gregorio Marañón), M Alva Blanchi(Research Institute Hospital 12 de Octubre), C G Toccheti(Federico II University Hospital), I Marquez-Roda(Hospital General Universitario Gregorio Marañón), Enrique Ortega‐Sollero(Spanish National Centre for Cardiovascular Research)
Cited by 0
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
|European Heart Journal|2016|2.5k
2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed Under the Auspices of the ESC Committee for Practice Guidelines
|European Journal of Heart Failure|2016|1.8k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
|European Heart Journal|2021|589